MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model

Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib

(2016) Shao-Lai Zhou et al.   GASTROENTEROLOGY

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

(2016) Vinit Kumar et al.   TRENDS IN IMMUNOLOGY

Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma

(2015) V. L. Bridgeman et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1

(2015) Edwin Jousma et al.   PEDIATRIC BLOOD & CANCER

CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer

(2015) Ming T. Cheah et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype

(2015) Katia Beider et al.   Oncotarget

Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy

(2013) N S Vasudev et al.   BRITISH JOURNAL OF CANCER

Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways

(2013) Patrick L. Raber et al.   INTERNATIONAL JOURNAL OF CANCER

Reduced Immunosuppressive Properties of Axitinib in Comparison with Other Tyrosine Kinase Inhibitors

(2013) Franziska Stehle et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy

(2013) Minoru Kobayashi et al.   MEDICAL ONCOLOGY

Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells

(2013) David J Panka et al.   Molecular Cancer

Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment

(2013) V. T. Phan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: Optimizing patient benefit

(2012) Stéphane Oudard et al.   CANCER TREATMENT REVIEWS

Treatment selection in metastatic renal cell carcinoma: expert consensus

(2012) Bernard Escudier et al.   Nature Reviews Clinical Oncology

Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients

(2012) Camillo Porta et al.   ONCOLOGY

Clinically relevant fatigue in recurrence-free prostate cancer survivors

(2011) D. J. Storey et al.   ANNALS OF ONCOLOGY

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis

(2011) M J M Gooden et al.   BRITISH JOURNAL OF CANCER

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy

(2011) James Finke et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression

(2011) Liang Zhang et al.   PLoS One

HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors

(2010) F. Shojaei et al.   CANCER RESEARCH

Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

(2010) D. Huang et al.   CANCER RESEARCH

Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma

(2010) D. Huang et al.   CANCER RESEARCH

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

(2010) E. B. Haura et al.   CLINICAL CANCER RESEARCH

Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study

(2010) H. J. Hammers et al.   MOLECULAR CANCER THERAPEUTICS

Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib

(2010) J C Welti et al.   ONCOGENE

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

(2009) Kristy J. Gotink et al.   ANGIOGENESIS

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

(2009) J. S. Ko et al.   CLINICAL CANCER RESEARCH

Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography–electrospray ionization-tandem mass spectrometry and pharmacokinetic application

(2009) Qingyu Zhou et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models

(2009) F. Shojaei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy

(2008) B. B. Friday et al.   CLINICAL CANCER RESEARCH